Integration of metabolomics and transcriptomics to reveal potential biomarkers associated with treatment response of neoadjuvant therapy in HER2+breast cancer

被引：0
|
作者：
Zhang, N. [1 ]
Xiang, Y. [1 ]
Jing, Z. [1 ]
Yu, F. [1 ]
Zeng, J. [1 ]
Pan, X. [1 ]
Zhou, W. [1 ]
Liang, X. [1 ]
Yue, Y. [1 ]
Zhang, H. [1 ]
Deng, Y. [1 ]
Deng, S. [1 ]
Mo, S. [1 ]
Jiang, X. [1 ]
Zeng, X. [1 ]
机构：
[1] Chongqing Univ, Breast Canc Ctr, Canc Hosp, Chongqing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2893
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
169P
引用
收藏
页码：S249 / S249
页数：1
相关论文
共 50 条
  • [41] Association of clinical biomarkers and response to neoadjuvant therapy in breast cancer
    Feeney, Gerard
    Waldron, Ronan
    Miller, Nicola
    Malone, Carmel
    Sweeney, Karl
    McLaughlin, Raymond
    Lowery, Aoife
    Barry, Kevin
    Kerin, Michael
    IRISH JOURNAL OF MEDICAL SCIENCE, 2024, 193 (02) : 605 - 613
  • [42] Association of clinical biomarkers and response to neoadjuvant therapy in breast cancer
    Gerard Feeney
    Ronan Waldron
    Nicola Miller
    Carmel Malone
    Karl Sweeney
    Raymond McLaughlin
    Aoife Lowery
    Kevin Barry
    Michael Kerin
    Irish Journal of Medical Science (1971 -), 2024, 193 : 605 - 613
  • [43] The optimal neoadjuvant treatment regimen for HR+/HER2+breast cancer: a network meta-analysis
    Wang, Hao
    Liu, Shiwei
    Yu, Miao
    Mi, Kun
    Mou, Exian
    Xia, Li
    Xie, Weimin
    Tang, Hao
    Feng, Yajing
    Yu, Xin
    CANCER RESEARCH, 2024, 84 (09)
  • [44] PPARγ loss increases the metastatic potential of HER2+breast cancer
    Lightbody, Elizabeth D.
    O'Connell, Kathleen M. J.
    Newton, Hailey T.
    Rubino, Rachel R.
    Apostoli, Anthony J.
    Ren, Kevin
    SenGupta, Sandip K.
    Nicol, Christopher J.
    CANCER RESEARCH, 2018, 78 (13)
  • [45] Optimizing combination therapy in a murine model of HER2+breast cancer?
    Lima, Ernesto A. B. F.
    Wyde, Reid A. F.
    Sorace, Anna G.
    Yankeelov, Thomas E.
    COMPUTER METHODS IN APPLIED MECHANICS AND ENGINEERING, 2022, 402
  • [46] Engineered nanomaterials as an effective tool for HER2+breast cancer therapy
    Pandey, Prashant
    Arya, Dilip Kumar
    Ramar, Mohan Kumar
    Chidambaram, Kumarappan
    Rajinikanth, P. S.
    DRUG DISCOVERY TODAY, 2022, 27 (09) : 2526 - 2540
  • [47] The addition of neoadjuvant pertuzumab for the treatment of HER2+breast cancer: a cost estimate with real-world data
    Borges, Andreia
    Pereira, Filipa
    Redondo, Patricia
    Antunes, Luis
    Vieira, Claudia
    Antunes, Pedro
    Bento, Maria Jose
    Sousa, Susana
    Lopes, Jose Machado
    Rocha-Goncalves, Francisco
    de Sousa, Joaquim Abreu
    Pereira, Deolinda Sousa
    Borges, Marina
    HEALTH ECONOMICS REVIEW, 2021, 11 (01)
  • [48] The optimal neoadjuvant treatment strategy for HR+/HER2+breast cancer: a network meta-analysis
    Liu, Shiwei
    Yu, Miao
    Mou, Exian
    Wang, Meihua
    Liu, Shuanghua
    Xia, Li
    Li, Hui
    Tang, Hao
    Feng, Yajing
    Yu, Xin
    Mi, Kun
    Wang, Hao
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [49] Interaction between redox regulation, immune activation, and response to treatment in HER2+breast cancer
    Luz, Paulo
    Ramos, Sofia
    Oliveira, Maria Jose
    Costa, Joao G.
    Saraiva, Nuno
    Fernandes, Ana S.
    REDOX BIOLOGY, 2025, 82
  • [50] Response of HER2+breast cancer patients to allogeneic cell immunotherapy
    Har-Noy, Michael
    Lausoontornsiri, Wirote
    Or, Reuven
    Katsanis, Emmanual
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345